ZOFRAN 8 MG — DIN 02213575
ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG · NOVARTIS PHARMACEUTICALS CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ZOFRAN?
ZOFRAN 8 MG contains ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02213575, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 14-Mar-2017. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ZOFRAN used for?
Prevention of nausea and vomiting associated with emetogenic chemotherapy and radiotherapy; prevention and treatment of post-operative nausea and vomiting.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ondansetron cost around the world?
Ondansetron is listed on 17 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 20 | 96 | AUD███.██ |
| Sweden | AIP (pharmacy purchase price) | 13 | 60 | SEK███.██ |
| United States | acquisition | 6 | 60 | USD███.██ |
| Saudi Arabia | public | 34 | 55 | SAR███.██ |
| South Africa | single exit price | 43 | 49 | ZAR███.██ |
| Bahrain | retail (max) | 15 | 33 | BHD███.██ |
| Greece | producer price (ex-factory) | 29 | 29 | EUR███.██ |
| Morocco | PPV (public price) | 11 | 29 | MAD███.██ |
| Czechia | max producer price (ex-factory) | 8 | 12 | CZK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 11 | 11 | EUR███.██ |
| United Kingdom | hospital | 10 | 10 | GBP███.██ |
| United Arab Emirates | public | 6 | 8 | AED███.██ |
| Spain | PVP con IVA (public price) | 8 | 8 | EUR███.██ |
| Romania | max producer price | 7 | 8 | RON███.██ |
| Hungary | producer price (ex-factory) | 5 | 7 | HUF███.██ |
| Norway | max AUP (pharmacy retail) | 3 | 4 | NOK███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
480 pack listings across 230 brand entries and 15 price bases, refreshed 08 Sep 2026. Ranges span every Ondansetron pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Ondansetron in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
43 holders have a Canadian DIN containing Ondansetron, across 135 DINs, of which 59 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 13 | 7 | JAMP ONDANSETRON, JAMP ONDANSETRON ODF, JAMP ONDANSETRON ODT, JAMP ONDANSETRON TABLETS, JAMP-ONDANSETRON, +1 more | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 9 | 7 | ONDANSETRON HYDROCHLORIDE DIHYDRATE INJECTION, ONDANSETRON INJECTION USP -(PRESERVATIVE FREE), ONDANSETRON INJECTION USP -(WITH PRESERVATIVE), ONDANSETRON ODT, SANDOZ ONDANSETRON, +1 more | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 8 | 5 | IPG-ONDANSETRON, MAR-ONDANSETRON, MAR-ONDANSETRON ODT, ONDANSETRON INJECTION USP | Sourceable in Canada |
| AURO PHARMA INC | 6 | 5 | AURO-ONDANSETRON INJECTION, AURO-ONDANSETRON ODT, ONDANSETRON INJECTION BP | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 5 | 5 | MINT-ONDANSETRON, MINT-ONDANSETRON ODT, MINT-ONDANSETRON SOLUTION | Sourceable in Canada |
| ACCEL PHARMA INC | 4 | 4 | ACCEL-ONDANSETRON, ACCEL-ONDANSETRON ODT | Sourceable in Canada |
| PHARMASCIENCE INC | 4 | 4 | PMS-ONDANSETRON, PMS-ONDANSETRON ODT | Sourceable in Canada |
| SANIS HEALTH INC | 4 | 4 | ONDANSETRON, ONDANSETRON ODT | Sourceable in Canada |
| APOTEX INC | 3 | 3 | APO-ONDANSETRON | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 2 | ONDANSETRON INJECTION, TEVA-ONDANSETRON | Sourceable in Canada |
| EUGIA PHARMA INC. | 4 | 2 | EUGIA-ONDANSETRON INJECTION, ONDANSETRON INJECTION BP | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 4 | 2 | MYLAN-ONDANSETRON, ONDANSETRON INJECTION, USP | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 8 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Tablets: blister packs of 10. ODT: 2 x 5 unit dose blisters. Oral Solution: 50 mL bottles. Injection: 2 mL and 4 mL ampoules in boxes of 5. |
| Storage | Not explicitly detailed in provided text snippet (refers to section 11), but mentions stability of diluted solutions for up to 2-7 days depending on conditions. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Ondansetron |
|---|---|
| ATC code | A04AA01 |
| AHFS class | 56:22.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02213575 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2213575 |
| Brand name | ZOFRAN |
| Generic / active ingredient | ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | A04AA01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A04AA |
| Current status | CANCELLED POST MARKET |
| Status date | 14-Mar-2017 |
| Original market date | 1991-12-30 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 8-16 mg IV or 8-16 mg orally depending on indication. Max IV dose 16 mg. Infuse IV over 15 mins. Hepatic impairment: max 8 mg/day. Follow specific guidelines for elderly to reduce cardiac risk.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or any components; concomitant use of apomorphine (due to risk of profound hypotension and loss of consciousness).
Warnings and precautions
Dose-dependent QTc prolongation; risk of Torsade de Pointes; myocardial ischemia and coronary artery spasm; serotonin syndrome; avoid in congenital long QT syndrome.
Is Ondansetron in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
59 of 135 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-ONDANSETRON | 8 MG | TABLET | ACCEL PHARMA INC | MARKETED | 02478935 |
| ACCEL-ONDANSETRON | 4 MG | TABLET | ACCEL PHARMA INC | MARKETED | 02478927 |
| ACCEL-ONDANSETRON ODT | 4 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | 02535319 |
| ACCEL-ONDANSETRON ODT | 8 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | 02535327 |
| APO-ONDANSETRON | 4 MG | TABLET | APOTEX INC | MARKETED | 02288184 |
| APO-ONDANSETRON | 8 MG | TABLET | APOTEX INC | MARKETED | 02288192 |
| APO-ONDANSETRON | 4 MG / 5 ML | SOLUTION | APOTEX INC | MARKETED | 02291967 |
| AURO-ONDANSETRON INJECTION | 2 MG | SOLUTION | AURO PHARMA INC | MARKETED | 02491524 |
| AURO-ONDANSETRON INJECTION | 2 MG | SOLUTION | AURO PHARMA INC | MARKETED | 02491532 |
| AURO-ONDANSETRON ODT | 4 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | 02511282 |
2 · Same class — other molecules in ATC A04AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ondansetron | ACCEL-ONDANSETRON · ACCEL-ONDANSETRON ODT · AG-ONDANSETRON · APO-ONDANSETRON · +53 more | 135 | 59 | Yes |
| Granisetron | APO-GRANISETRON · GRANISETRON HYDROCHLORIDE INJECTION · GRANISETRON HYDROCHLORIDE INJECTION SDZ · GRANISETRON HYDROCHLORIDE INJECTION USP · +4 more | 10 | 3 | Yes |
| Palonosetron | ALOXI | 2 | 1 | Yes |
| Palonosetron, Combinations | AKYNZEO | 1 | 1 | Yes |
| Dolasetron | ANZEMET · ANZEMET INJECTION 20 MG/ML | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A04AD | Aprepitant · Dronabinol · Nabilone · Other Antiemetics · Scopolamine | 29 | 14 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ZOFRAN called?
The same molecule, Ondansetron, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ondansetron Bluefish | Latin | Norway, Sweden |
| Dantron | Latin | Morocco, South Africa |
| Ondansetron Abacus Medicine | Latin | Sweden |
| Ondansetron Ebb | Latin | Sweden |
| APX-Ondansetron | Latin | Australia |
| APX-Ondansetron ODT | Latin | Australia |
| CHEMOSET | Latin | Morocco |
| Ondansetron EQL Pharma | Latin | Sweden |
| Ondansetron ODT Viatris | Latin | Australia |
| Ondansetron ODT-DRLA | Latin | Australia |
| ONDANSETRON ODT-WGR | Latin | Australia |
| Ondansetron SZ | Latin | Australia |
| Ondansetron SZ ODT | Latin | Australia |
| Ondansetron Tablets Viatris | Latin | Australia |
| Ondansetron Teva | Latin | Czechia, Sweden |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.